Last reviewed · How we verify
NCT06662695
Ginger and Plasma Cholesterol Efflux Capacity
NA trial testing Ginger-based supplement in Healthy in 35 participants. Completed in 7 April 2025.
1 March 2025
Quick facts
| Lead sponsor | Shahid Beheshti University of Medical Sciences |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | triple |
| Primary purpose | prevention |
| Enrollment | 35 |
| Start date | 3 November 2024 |
| Primary completion | 1 March 2025 |
| Estimated completion | 7 April 2025 |
| Sites | 1 location across Iran |
Drugs / interventions tested
- Ginger-based supplement
- Placebo
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
Shahid Beheshti University of Medical Sciences
Who can join
Adults 18 to 75, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In light of the findings from experimental studies examining the effects of ginger-derived compounds on cholesterol efflux pathways, this study aims to investigate the impact of oral ginger supplementation on high-density lipoprotein (HDL) function. The crossover and double-blind study will be conducted in two four-week periods, with a minimum of three weeks between these two phases. In one of the two study periods, participants will receive a ginger supplement, while in the other period, they will receive a placebo in the form of capsules. At the outset and end of each study period, venous blood samples will be obtained from the subjects. Plasma and buffy coat (containing white blood cells) will be separated and stored at -80. Cholesterol efflux capacity (CEC) will be determined by adding participants' plasma samples to the culture medium of THP-1 cells. Additionally, the gene expression of ATP-binding cassette transporters (ABCA1) and ABCG1 will be determined in the tissue lining obtained from the blood samples of the participants.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06662695
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other Shahid Beheshti University of Medical Sciences trials
Trials by the same sponsor.
- NCT07005687 — Using MSCs for Chronic Active Antibody Mediated Rejection · NA · not yet recruiting
- NCT07435558 — Homogeneous vs. Heterogeneous Learning Style Grouping in Problem-Based Learning Among Nurses · NA · not yet recruiting
- NCT07408492 — Impact of AI-Based Research Training on Nursing Students · NA · not yet recruiting
- NCT07176663 — Efficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure · NA · not yet recruiting
- NCT07291622 — Synchrony-Optimized Non-Invasive Ventilation Education Program and ICU Patients · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06662695 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shahid Beheshti University of Medical Sciences
- Last refreshed: 9 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06662695.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing